Comparison of substrate metabolism by wild type CYP2D6 protein and a variant containing methionine, not valine, at position 374.

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Pharmacogenetics (London)

• Publication date

  1995-08-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1097/00008571-199508000-00007PMID 8528270
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• An inactive cytochrome P450 CYP2D6 allele containing a deletion and a base substitution

  1995cited by this paper
• Site-directed mutagenesis of putative substrate recognition sites in cytochrome P450 2B11: importance of amino acid residues 114, 290, and 363 for substrate specificity.

  1994cited by this paper
• Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily.

  1993cited by this paper
• Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes.

  1993cited by this paper
• Characterization of a human cell line expressing high levels of cDNA-derived CYP2D6.

  1993cited by this paper
• A single amino acid substitution confers progesterone 6 beta-hydroxylase activity to rabbit cytochrome P450 2C3.

  1993cited by this paper
• Predicting the cytochrome P450 mediated metabolism of xenobiotics.

  1993cited by this paper
• Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences.

  1992cited by this paper
• Catalytic activities of human debrisoquine 4-hydroxylase cytochrome P450 (CYP2D6) expressed in yeast.

  1992cited by this paper
• Metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in human lung and liver microsomes and cytochromes P-450 expressed in hepatoma cells.

  1992cited by this paper
• Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype.

  1991cited by this paper
• A three-dimensional molecular template for substrates of human cytochrome P450 involved in debrisoquine 4-hydroxylation.

  1991cited by this paper
• A tobacco smoke-derived nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, is activated by multiple human cytochrome P450s including the polymorphic human cytochrome P4502D6.

  1991cited by this paper
• Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes.

  1990cited by this paper
• Identification of the primary gene defect at the cytochrome P450 CYP2D locus

  1990cited by this paper
• Sequence requirements for cytochrome P-450IID1 catalytic activity. A single amino acid change (Ile380 Phe) specifically decreases Vmax of the enzyme for bufuralol but not debrisoquine hydroxylation.

  1990cited by this paper
• Lung cancer and the debrisoquine metabolic phenotype.

  1990cited by this paper
• The human CYP2D locus associated with a common genetic defect in drug oxidation: a G1934----A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3' splice recognition site.

  1990cited by this paper
• The genetic polymorphism of debrisoquine/sparteine metabolism--clinical aspects.

  1990cited by this paper
• Evidence in humans for variant allozymes of the nondeficient sparteine/debrisoquine monooxygenase (P45OIID 1) in vitro.

  1989cited by this paper
• The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene.

  1989cited by this paper
• Alteration of mouse cytochrome P450coh substrate specificity by mutation of a single amino-acid residue

  1989cited by this paper
• Lung cancer risk, occupational exposure, and the debrisoquine metabolic phenotype.

  1989cited by this paper
• Characterization of the common genetic defect in humans deficient in debrisoquine metabolism

  1988cited by this paper
• Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs.

  1988cited by this paper
• Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes.

  1988cited by this paper
• Antibodies against human cytochrome P-450db1 in autoimmune hepatitis type II.

  1988cited by this paper
• High-performance liquid chromatographic assays for bufuralol 1'-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver.

  1987cited by this paper
• Debrisoquine/sparteine-type polymorphism of drug oxidation. Purification and characterization of two functionally different human liver cytochrome P-450 isozymes involved in impaired hydroxylation of the prototype substrate bufuralol.

  1986cited by this paper
• Quantitative analysis of metoprolol and three of its metabolites in urine and liver microsomes by high-performance liquid chromatography.

  1985cited by this paper
• Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism.

  1985cited by this paper
• Metabolic oxidation phenotypes as markers for susceptibility to lung cancer

  1984cited by this paper
• Defective N-oxidation of sparteine in man: A new pharmacogenetic defect

  1979cited by this paper
• Hepatic triphosphopyridine nucleotide-cytochrome c reductase: isolation, characterization, and kinetic studies.

  1962cited by this paper

• Effects of standardized medicinal plant extracts on drug metabolism mediated by CYP3A4 and CYP2D6 enzymes.

  2020cites this paper
• Contribution of Human Liver and Intestinal Carboxylesterases to the Hydrolysis of Selexipag In Vitro.

  2019cites this paper
• The Interaction of Antiparasitic Drugs with the Drug-metabolising Cytochrome P450s (CYPs) and Characterisation of a CYP Variant Unique to African Populations.

  2012cites this paper
• Crystal Structure of Human Cytochrome P450 2D6 with Prinomastat Bound*

  2012cites this paper
• Big Tobacco and the human genome: driving the scientific bandwagon?

  2009cites this paper
• In vitro measurements of metabolism for application in pharmacokinetic modeling.

  2008cites this paper
• Roles of phenylalanine at position 120 and glutamic acid at position 222 in the oxidation of chiral substrates by cytochrome P450 2D6.

  2006cites this paper
• 3,4-Dehydrodebrisoquine, a Novel Debrisoquine Metabolite Formed from 4-Hydroxydebrisoquine That Affects the CYP2D6 Metabolic Ratio

  2006cites this paper
• DMD # 8920 3 , 4-DEHYDRODEBRISOQUINE , A NOVEL DEBRISOQUINE METABOLITE FORMED FROM 4-HYDROXYDEBRISOQUINE THAT IMPACTS THE CYP 2 D 6 METABOLIC RATIO

  2006cites this paper
• Genetically modified mouse models for pharmacogenomic research

  2004cites this paper
• In-vitro Drug Metabolism Studies During Development of New Drugs

  2004cites this paper
• CYTOCHROME P 450 IN VITRO REACTION PHENOTYPING : A RE-EVALUATION OF APPROACHES USED FOR P 450 ISOFORM IDENTIFICATION

  2003cites this paper
• Role of glutamic acid 216 in cytochrome P450 2D6 substrate binding and catalysis.

  2003cites this paper
• Cytochrome P450 in vitro reaction phenotyping: a re-evaluation of approaches used for P450 isoform identification.

  2003cites this paper
• Diversity in the oxidation of substrates by cytochrome P450 2D6: lack of an obligatory role of aspartate 301-substrate electrostatic bonding.

  2002cites this paper
• The molecular and enzyme kinetic basis for the diminished activity of the cytochrome P450 2D6.17 (CYP2D6.17) variant. Potential implications for CYP2D6 phenotyping studies and the clinical use of CYP2D6 substrate drugs in some African populations.

  2002cites this paper
• Oxidation of Methoxyphenethylamines by Cytochrome P450 2D6

  2002cites this paper
• Diversity in Mechanisms of Substrate Oxidation by Cytochrome P450 2D6

  2001cites this paper
• Heterologous expression of cytochrome P450 2D6 mutants, electron transfer, and catalysis of bufuralol hydroxylation: the role of aspartate 301 in structural integrity.

  2001cites this paper
• Coumarin substrates for cytochrome P450 2D6 fluorescence assays.

  2001cites this paper
• Role of polymorphic CYP2E1 and CYP2D6 genes in NNK-induced chromosome aberrations in cultured human lymphocytes.

  2000cites this paper
• Regioselective hydroxylation of debrisoquine by cytochrome P4502D6: implications for active site modelling

  2000cites this paper
• Species difference in enantioselectivity for the oxidation of propranolol by cytochrome P450 2D enzymes.

  2000cites this paper
• A novel assay for detecting antibodies to cytochrome P4502D6, the molecular target of liver kidney microsomal antibody type 1.

  1999cites this paper
• The use of Long-term Hepatocyte Cultures for Detecting Induction of Drug Metabolising Enzymes: The Current Status

  1999cites this paper
• Polymorphic Cytochromes P450 and Drugs Used in Psychiatry

  1999cites this paper
• Role of a potent inhibitory monoclonal antibody to cytochrome P-450 3A4 in assessment of human drug metabolism.

  1999cites this paper
• Enantioselectivity of bunitrolol 4-hydroxylation is reversed by the change of an amino acid residue from valine to methionine at position 374 of cytochrome P450-2D6.

  1999cites this paper
• In vitro assessment of human cytochrome P450.

  1998cites this paper
• Functional co-expression of CYP2D6 and human NADPH-cytochrome P450 reductase in Escherichia coli.

  1998cites this paper
• Pharmacokinetics and metabolism of bisoprolol enantiomers in humans.

  1998cites this paper
• Stereoselective metabolism of bisoprolol enantiomers in dogs and humans.

  1998cites this paper
• Detection and characterization of novel polymorphisms in the CYP2E1 gene.

  1998cites this paper
• Functional properties of CYP2D6 1 (wild-type) and CYP2D6 7 (His324Pro) expressed by recombinant baculovirus in insect cells

  1997influential citation
• Development of a human lymphoblastoid cell line constitutively expressing human CYP1B1 cDNA: substrate specificity with model substrates and promutagens.

  1997cites this paper
• Development of a V79 cell line expressing human cytochrome P450 2D6 and its application as a metabolic screening tool.

  1997cites this paper
• The CYP2D6 extensive metabolizer genotype is associated with increased risk for bladder cancer.

  1997cites this paper
• Use of cDNA-expressed human cytochrome P450 enzymes to study potential drug-drug interactions.

  1997cites this paper
• Molecular modelling of cytochrome P4502D6 (CYP2D6) based on an alignment with CYP102: structural studies on specific CYP2D6 substrate metabolism.

  1997cites this paper
• CYP2D6 is the principal cytochrome P450 responsible for metabolism of the histamine H1 antagonist promethazine in human liver microsomes.

  1996cites this paper